Products
Online Inquiry
Bimiralisib
Cat. No.:
0225LY-0583
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Bimiralisib is an orally available pan-inhibitor of PI3K (alpha, beta, delta, gamma) and mTOR; by targeting these pathways, it inhibits growth and induces apoptosis in cells where PI3K/mTOR is overexpressed.
Synonym:
5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 1225037-39-7; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 2-Pyridinamine, 5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-Di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-2-pyridinamine; 5-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine
CAS No.:
1225037-39-7
Compound CID:
58507717
Formula:
C17H20F3N7O2
Formula Weight:
411.38
Specification
Targets&IC50:
PI3Kγ: 25 nM(Kd); mTOR: 12 nM(Kd); PI3Kα: 1.5 nM(Kd); PI3Kβ: 11 nM(Kd); PI3Kδ: 25 nM(Kd)
Relative Density:
1.418 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Bimiralisib can be used in clinical oncology research to investigate the dual inhibition of PI3K and mTOR in solid tumors.
Library Information
Target:
PI3K; mTOR; S6 Kinase
Receptor:
mTOR; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; pPKB; pS6
Pathways:
PI3K/Akt/mTOR signaling; MAPK
Plate Number:
AOCL-8
Plate Location:
e8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
5 mg/mL; 12.15 mM
ALogP:
1.891
HBA_Count:
6
HBD_Count:
1
Rotatable Bond:
4
